tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod
PremiumThe FlyCervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod
27d ago
CervoMed’s Promising First-Mover Advantage in Dementia with Lewy Bodies Treatment: Buy Rating Reaffirmed
Premium
Ratings
CervoMed’s Promising First-Mover Advantage in Dementia with Lewy Bodies Treatment: Buy Rating Reaffirmed
1M ago
CervoMed Reports Q3 2025 Financial Results and Progress
Premium
Company Announcements
CervoMed Reports Q3 2025 Financial Results and Progress
2M ago
CervoMed upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe FlyCervoMed upgraded to Buy from Neutral at H.C. Wainwright
2M ago
CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating
Premium
Ratings
CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating
2M ago
CervoMed announces FDA alignment on neflamapimod registration path
Premium
The Fly
CervoMed announces FDA alignment on neflamapimod registration path
2M ago
Cervomed Inc.’s Promising Phase 2a Study on Neflamapimod for Aphasia
PremiumCompany AnnouncementsCervomed Inc.’s Promising Phase 2a Study on Neflamapimod for Aphasia
2M ago
CervoMed Releases Investor Presentation on Website
Premium
Company Announcements
CervoMed Releases Investor Presentation on Website
2M ago
CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating
Premium
Ratings
CervoMed’s Strategic Phase 3 Trial Plans and Financial Outlook Justify Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100